Twist Bioscience Increased FY24 Revenue Guidance To $288M To $293M Versus Prior Guidance Of $285M-$290M Versus Consensus Of $289.69M
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has raised its FY24 revenue guidance to a range of $288M to $293M, up from the previous forecast of $285M to $290M. This new guidance surpasses the consensus estimate of $289.69M.
February 02, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience has increased its FY24 revenue guidance, now expecting $288M to $293M, exceeding both its prior forecast and the consensus estimate.
Raising revenue guidance typically signals a company's strong performance and optimistic future outlook, which can positively influence investor sentiment and potentially lead to a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100